Literature DB >> 1993944

Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome.

R L Siegler1, M K Milligan, T H Burningham, R D Christofferson, S Y Chang, L B Jorde.   

Abstract

We examined 61 patients an average of 9.6 years (range 5 to 18 years) after an episode of childhood hemolytic-uremic syndrome. Twenty-four (39%) had one or more abnormalities. Seven (11%) had proteinuria and six (10%) had low creatinine clearance as solitary abnormalities. Eight (13%) had both proteinuria and reduced creatinine clearance; three (5%) had a combination of hypertension, proteinuria, and low creatinine clearance. Abnormalities sometimes appeared after an interval of apparent recovery. Logistic regression analysis showed that duration of anuria was the best predictor of disease at follow-up. No patients who had anuria lasting longer than 8 days or oliguria exceeding 15 days escaped chronic disease. However, 45% of those with disease had no anuria, and a third had no oliguria. Physicians should therefore be cautious in assuming recovery from HUS on the basis of a single evaluation and should periodically evaluate patients for an extended period.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993944     DOI: 10.1016/s0022-3476(05)80482-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  31 in total

1.  Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005.

Authors:  K G J Pollock; D Young; T J Beattie; W T A Todd
Journal:  Epidemiol Infect       Date:  2007-03-05       Impact factor: 2.451

2.  Control of enterohaemorrhagic Escherichia coli infection: the need for a network involving microbiological laboratories and clinical and public health institutions.

Authors:  H Karch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

Review 3.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

4.  A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7.

Authors:  R Lissner; H Schmidit; H Karch
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

5.  Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.

Authors:  M Bielaszewska; I Clarke; M A Karmali; M Petric
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome.

Authors:  Brent R Weil; Sharon P Andreoli; Deborah F Billmire
Journal:  Pediatr Nephrol       Date:  2010-04-27       Impact factor: 3.714

7.  Risk factors for poor renal prognosis in children with hemolytic uremic syndrome.

Authors:  Alessandra Gianviti; Alberto E Tozzi; Laura De Petris; Alfredo Caprioli; Lucilla Ravà; Alberto Edefonti; Gianluigi Ardissino; Giovanni Montini; Graziella Zacchello; Alfonso Ferretti; Carmine Pecoraro; Tommaso De Palo; Angela Caringella; Maurizio Gaido; Rosanna Coppo; Francesco Perfumo; Nunzia Miglietti; Ilse Ratsche; Rosa Penza; Giovambattista Capasso; Silvio Maringhini; Salvatore Li Volti; Carmen Setzu; Marco Pennesi; Alberto Bettinelli; Leopoldo Peratoner; Ivana Pela; Elio Salvaggio; Giuliana Lama; Salvatore Maffei; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2003-10-31       Impact factor: 3.714

8.  Enterohemorrhagic colitis with disseminated intravascular coagulation.

Authors:  Gregory Taroyan; Andrew L Juergens
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-14

9.  Blood pressure in the long-term follow-up of children with hemolytic uremic syndrome.

Authors:  Laura De Petris; Alessandra Gianviti; Ugo Giordano; Armando Calzolari; Alberto E Tozzi; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2004-11       Impact factor: 3.714

Review 10.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.